Health tech company TidalSense has closed a £7.5m fundraising round.
The round was led by investors BGF and Downing, with the capital going towards building out TidalSense’s diagnostics business further and targeting the primary care and diagnostics provider market in the UK.
Cambridge-based TidalSense has created a handheld medical device (N-Tidal) that detects changes in lung function sensitively and enables quicker, more accurate and automated diagnosis of chronic obstructive pulmonary disease (COPD), with asthma to follow.
TidalSense CEO, Dr Ameera Patel, said:
“Quick, reliable and accurate diagnostics have the potential to slash waiting lists and slow the trajectory of respiratory diseases.
“That’s why we’ve developed N-Tidal, which will enable earlier, accurate detection of COPD and will result in better patient outcomes and reduced costs for healthcare environments in the long-term.”
COPD and asthma currently affect 1/10 of the world’s population, and that figure is rising steadily.
Early detection and diagnosis have the potential to slow the trajectory of the disease and globally, the COPD and asthma diagnostics and monitoring market is estimated to be $8.2 billion (£6.5 billion) per year.
However, current testing for COPD and asthma involve spirometry – an 1840s technology which takes 30 minutes per test and which has a number of known shortfalls.
The process is widely known to be uncomfortable for patients, requires specialist training, is time-consuming for both patients and clinicians and often leading to misdiagnosis.
Furthermore, testing stopped during the pandemic and has had little pick up since, impacting already stretched patient waiting times further.
It is estimated that in England alone, 200-250 per 500,000 of the population are awaiting a diagnostic test driving waiting times of up to 5-10 years.
N-Tidal’s diagnostic test will be delivered at the point of care, can be completed within less than five minutes and requires no specialist training.
The test relies on relaxed breathing, eliminating technique-dependence and therefore reducing misdiagnosis.
Furthermore, a preliminary usability study shows that 99 per cent of patients agree that they find the test easy to perform.
The device has been used on over 1,000 patients, collecting over 2.3 million breaths from patients through clinical studies and trials.
Using this data and the company’s AI platform, N-Tidal can provide near-real-time analysis of patient lung health and can provide a diagnosis within minutes.
Tim Rea, Head of Early Stage Investments at BGF commented:
“The number of people living with respiratory diseases, particularly COPD and asthma, is rising globally, yet diagnosis and management are poor and expensive.
“The current standard of care leads to increased hospitalisations and deaths, and puts additional burden onto already stretched healthcare systems.
“TidalSense’s solution is a prime example of where advanced machine learning techniques can be applied to deliver faster diagnostics, greater efficiencies and better patient outcomes.”
Matt Pierce, Investment Director at Downing, added:
“The UK currently has some extremely exciting R&D projects in the med-tech and life science sectors, which are attracting both investment and attention.
“TidalSense is a company which is a front-runner in cutting-edge, healthcare AI innovation, an area which has strategic importance to the UK and which also reflects global growth and demand.”